Asymmetric dimethylarginine in angiotensin II-induced hypertension
- 1 March 2010
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 298 (3) , R740-R746
Abstract
Recent studies have shown that asymmetric dimethylarginine (ADMA), a nitric oxide synthase inhibitor, is increased in hypertension and chronic kidney disease. However, little is known about the effects of hypertension per se on ADMA metabolism. The purpose of this study was to test the hypothesis that ANG II-induced hypertension, in the absence of renal injury, is associated with increased oxidative stress and plasma and renal cortex ADMA levels in rats. Male Sprague-Dawley rats were treated with ANG II at 200 ng·kg−1·min−1 sc (by minipump) for 1 or 3 wk or at 400 ng·kg−1·min−1 for 6 wk. Mean arterial pressure was increased after 3 and 6 wk of ANG II; however, renal injury (proteinuria, glomerular sclerosis, and interstitial fibrosis) was only evident after 6 wk of treatment. Plasma thiobarbituric acid reactive substances concentration and renal cortex p22phox protein abundance were increased early (1 and 3 wk), but urinary excretion of isoprostane and H2O2 was only increased after 6 wk of ANG II. An increased in plasma ADMA after 6 wk of ANG II was associated with increased lung protein arginine methyltransferase-1 abundance and decreased renal cortex dimethylarginine dimethylaminohydrolase activity. No changes in renal cortex ADMA were observed. ANG II hypertension in the absence of renal injury is not associated with increased ADMA; however, when the severity and duration of the treatment were increased, plasma ADMA increased. These data suggest that elevated blood pressure alone, for up to 3 wk, in the absence of renal injury does not play an important role in the regulation of ADMA. However, the presence of renal injury and sustained hypertension for 6 wk increases ADMA levels and contributes to nitric oxide deficiency and cardiovascular disease.Keywords
This publication has 51 references indexed in Scilit:
- Angiotensin II Decreases Nitric Oxide Synthase 3 Expression via Nitric Oxide and Superoxide in the Thick Ascending LimbHypertension, 2009
- Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertensionAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Effect of Telmisartan on Nitric Oxide–Asymmetrical Dimethylarginine SystemHypertension, 2008
- Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Determination of dimethylarginine dimethylaminohydrolase activity in the kidneyKidney International, 2007
- RNA Silencing In Vivo Reveals Role of p22
phox
in Rat Angiotensin Slow Pressor ResponseHypertension, 2006
- Asymmetrical Dimethylarginine, an Endogenous Nitric Oxide Synthase Inhibitor, in Experimental HypertensionHypertension, 1997
- Role of Nitric Oxide in Short-term and Prolonged Effects of Angiotensin II on Renal HemodynamicsHypertension, 1996
- Role of Nitric Oxide in Modulating the Vasoconstrictor Actions of Angiotensin II in Preglomerular and Postglomerular Vessels in DogsHypertension, 1995
- Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in ratsBiochemical and Biophysical Research Communications, 1987